3 d. ago China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Chinese drug maker 3SBio plans to raise HK$3.12 billion (US$401 million) by selling a 4.14 per cent stake in the company to fund clinical research in China and the US and expand the global reach of its drug portfolio. The Shenyang-based biopharmaceutical firm has agreed to sell 105.1 million new shares at HK$29.62 each. The placing price represents a 6.5 per cent discount compared with Monday’s closing price of HK$31.68, according to its filing with the Hong Kong stock exchange on Tuesday. The...

Economics

2 w. ago China’s clinical trial capacity matches US, attracts more global pharma firms

China’s growing pipeline of novel drug candidates is expected to draw increased attention from global pharmaceutical companies and investors scouting for licensing opportunities, as the country’s clinical trial capacity has expanded to match those in the US. That assessment was made by Shanghai-based Helen Chen, Greater China managing partner at L.E.K. Consulting, one of the most respected analysts in the mainland’s life sciences industry. “There is increased interest from multinational...

Politics

2 w. ago China’s clinical trial capacity matches US, attracts more global pharma firms, investors

China’s clinical trial capacity matches US, attracts more global pharma firms, investors  South China Morning Post

Economics

2 w. ago China’s Xpeng posts record revenue as robotaxi and humanoid ambitions take shape

Leading Chinese electric-vehicle (EV) maker Xpeng reported record quarterly revenue and sharply narrowed losses in the third quarter, even as its Hong Kong-listed shares fell on Monday after investors shrugged off a bullish call from JPMorgan. The Guangzhou-based firm’s net loss narrowed by nearly 80 per cent to 380.9 million yuan (US$53.6 million) in the third quarter from 1.81 billion yuan a year earlier, according to a filing to the Hong Kong stock exchange. Revenue surged 101.8 per cent year...

Politics

3 w. ago Simcere’s SIM0278 enters Phase II trial in China for atopic dermatitis

Simcere’s SIM0278 enters Phase II trial in China for atopic dermatitis  Clinical Trials Arena

Politics

3 w. ago Ignore China’s innovation boom ‘at your own peril’, General Atlantic CEO warns

Investors in the West are underestimating the scale of innovation, entrepreneurship and economic momentum happening in China, leading to missed opportunities, according to William Ford, chairman and CEO of US private equity firm General Atlantic. “Investors avoid investing in China at their own peril,” Ford said in an exclusive interview with the Post on the sidelines of the 2025 Family Business Summit in Hong Kong last week. “They’ll miss some tremendous investment opportunities.” Ford noted...

Events

4 w. ago Can Illumina’s (ILMN) Clinical Growth Offset Ongoing Regulatory Challenges in China?

Can Illumina’s (ILMN) Clinical Growth Offset Ongoing Regulatory Challenges in China?  Yahoo! Finance UK

Science